Latin America Pharmaceutical Products CMO Market, by Product Type (API and Ingredients, Finished Dosage Form, and Pharmaceutical Packaging) and by Country (Brazil, Mexico, Argentina, and Rest of Latin America), is estimated to be valued at US$ 15,173.6 million in 2020 and is expected to exhibit a CAGR of 14.7% over the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.
Increasing merger and acquisition activity among key player in the Latin America are major factors driving the market growth during the forecast period. For instance, in October 2019, Knight Therapeutics announced its plans to acquire Biotoscana Investments, a Brazil-based pharmaceutical company for US$ 281 million. In May 2019, Hapvida Participacoes e Investimentos SA acquired Sao Francisco Saude.
Increasing adoption of telemedicine is expected to aid in growth of the market. For instance, in March 2020, VivaBem, a digital health tech start-up based in Brazil, partnered with Doktor.se, a telemedicine provider based in Sweden, to expand its digital primary care services in Brazil.
Browse 09 Market Data Tables and 13 Figures spread through 151 Pages and in-depth TOC on “Latin America Pharmaceutical Products CMO Market”- Global Forecast to 2027, by Product Type (API and Ingredients, Finished Dosage Form, and Pharmaceutical Packaging) and by Country (Brazil, Mexico, Argentina, and Rest of Latin America),
To know the latest trends and insights prevalent in the Latin America Pharmaceutical Products CMO Market, click the link below:
Key Takeaways of the Latin America Pharmaceutical Products CMO Market:
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients